|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...5556575859606162636465...156157» |
- Trial primary completion date: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=2500, Enrolling by invitation, Sponsor: International Islamic University Malaysia
Trial primary completion date: May 2015 --> May 2016
- Trial primary completion date: Diamant: Cardiovascular Risk Factors After Single Pancreas Transplantation (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=30, Recruiting, Sponsor: Oslo University Hospital
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=270, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: May 2016 --> Oct 2016
- || Ruxience (rituximab-pvvr) / Pfizer
Trial primary completion date: Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=157, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: May 2016 --> Oct 2016 Trial primary completion date: Aug 2015 --> Mar 2016
- Enrollment closed, Trial primary completion date: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: McMaster University
Trial primary completion date: Aug 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016
- ||||| Benlysta (belimumab) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Sep 24, 2015
P3, N=400, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2017
- Prolia (denosumab) / Amgen, Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: Effects of Denosumab on the Pharmacokinetics of Etanercept (clinicaltrials.gov) - Sep 24, 2015
P1, N=17, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2017 Recruiting --> Active, not recruiting | N=44 --> 17 | Trial primary completion date: Sep 2015 --> Jan 2016
- | Biomarker, Trial completion, Enrollment change: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=40, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | N=44 --> 17 | Trial primary completion date: Sep 2015 --> Jan 2016 Active, not recruiting --> Completed | N=80 --> 40
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Tocilizumab for Patients With Giant Cell Arteritis (clinicaltrials.gov) - Sep 24, 2015
P2, N=30, Completed, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed | N=80 --> 40 Recruiting --> Completed
- ||| New trial: Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK. (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=1500, Recruiting, Sponsor: University of Glasgow
- New trial, Glucose variability: Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=15, Not yet recruiting, Sponsor: University of Virginia
- ||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
New trial: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=950, Recruiting, Sponsor: Celltrion
- ||||||| Symlin (pramlintide) / AstraZeneca
Trial completion: Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 23, 2015
P3, N=190, Completed, Sponsor: AstraZeneca
Recruiting --> Completed No longer recruiting --> Completed
- Enrollment change, Trial primary completion date: A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement (clinicaltrials.gov) - Sep 23, 2015
P4, N=5, Terminated, Sponsor: DePuy International
No longer recruiting --> Completed N=50 --> 5 | Trial primary completion date: Dec 2014 --> Oct 2007
- | cyclophosphamide / Generic mfg.
Trial completion: STOP-IgAN: Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy (clinicaltrials.gov) - Sep 23, 2015
P3, N=148, Completed, Sponsor: RWTH Aachen University
N=50 --> 5 | Trial primary completion date: Dec 2014 --> Oct 2007 Active, not recruiting --> Completed
- || Trial primary completion date: MD Logic Pump Advisor -Pediatric Study (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Sep 2016
- Enrollment closed, Trial primary completion date: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: University of Rochester
Trial primary completion date: Jul 2015 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion, Enrollment change: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=36, Completed, Sponsor: Rigshospitalet, Denmark
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed | N=45 --> 36
- Trial completion, Enrollment change, Trial primary completion date: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=12, Completed, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Completed | N=45 --> 36 Recruiting --> Completed | N=34 --> 12 | Trial primary completion date: Dec 2015 --> Sep 2015
- ||| New trial: APRAN: Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Isabelle Fortin
- ||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Enrollment closed, Trial primary completion date: Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov) - Sep 22, 2015
P2, N=84, Active, not recruiting, Sponsor: River Vision Development Corporation
Recruiting --> Completed | N=34 --> 12 | Trial primary completion date: Dec 2015 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2016
- ||||| dalfampridine / Generic mfg.
Enrollment closed: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Sep 21, 2015
P3, N=647, Active, not recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- ||||| dimethyl fumarate / Generic mfg.
Trial initiation date: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 21, 2015
P3, N=172, Not yet recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting Initiation date: Dec 2015 --> May 2016
- | dimethyl fumarate / Generic mfg.
Enrollment open: FOCUS: Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (clinicaltrials.gov) - Sep 21, 2015
P2, N=18, Recruiting, Sponsor: Biogen
Initiation date: Dec 2015 --> May 2016 Not yet recruiting --> Recruiting
- prednisone / Generic mfg.
Trial primary completion date: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Sep 21, 2015
P3, N=126, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Nov 2015
- Enrollment closed, Enrollment change, Trial primary completion date: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 20, 2015
P1, N=8, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Aug 2015 --> Nov 2015 Enrolling by invitation --> Active, not recruiting | N=24 --> 8 | Trial primary completion date: May 2016 --> Feb 2016
- Savella (milnacipran) / AbbVie, Pierre Fabre
Enrollment change, Trial withdrawal, HEOR: The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients (clinicaltrials.gov) - Sep 19, 2015
P4, N=0, Withdrawn, Sponsor: Loma Linda University
Enrolling by invitation --> Active, not recruiting | N=24 --> 8 | Trial primary completion date: May 2016 --> Feb 2016 N=50 --> 0 | Recruiting --> Withdrawn
- BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
Enrollment open: To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog (clinicaltrials.gov) - Sep 17, 2015
P1, N=36, Recruiting, Sponsor: Adocia
N=50 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New trial, Observational data, HEOR: An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=120, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Metoject (methotrexate autopen) / Medac
New P3 trial, Compliance: Self-i: Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe (clinicaltrials.gov) - Sep 17, 2015
P3, N=290, Recruiting, Sponsor: GECEM
- Enrollment change, Trial withdrawal, Stroma: Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis (clinicaltrials.gov) - Sep 17, 2015
P1/2, N=0, Withdrawn, Sponsor: Translational Biosciences
Not yet recruiting --> Recruiting N=20 --> 0 | Active, not recruiting --> Withdrawn
- Enrollment open, Trial initiation date, Trial primary completion date: Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=150, Recruiting, Sponsor: Gynuity Health Projects
N=20 --> 0 | Active, not recruiting --> Withdrawn Completed --> Recruiting | Initiation date: Jan 2011 --> Mar 2015 | Trial primary completion date: Mar 2013 --> Feb 2016
- Trial completion: Sudoscan in Patients With Autoimmune Disorders (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=85, Completed, Sponsor: The Catholic University of Korea
Completed --> Recruiting | Initiation date: Jan 2011 --> Mar 2015 | Trial primary completion date: Mar 2013 --> Feb 2016 Recruiting --> Completed
- New trial: Scorpio Non Restricted Geometry (NRG) Study in Japan (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=300, Recruiting, Sponsor: Stryker Japan K.K.
- New trial: Mitochondrial Dysfunction and Disease Progression (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=45, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | olendalizumab (ALXN1007) / AstraZeneca
Enrollment closed: Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome (clinicaltrials.gov) - Sep 15, 2015
P2a, N=20, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- || mezagitamab (TAK-079) / Takeda
Trial initiation date, Trial primary completion date: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants (clinicaltrials.gov) - Sep 14, 2015
P1, N=82, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting Initiation date: Aug 2014 --> Aug 2015 | Trial primary completion date: Jul 2015 --> Feb 2016
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Detemir: Role in Type 1 Diabetes (clinicaltrials.gov) - Sep 14, 2015
P4, N=13, Completed, Sponsor: Baylor College of Medicine
Initiation date: Aug 2014 --> Aug 2015 | Trial primary completion date: Jul 2015 --> Feb 2016 N=20 --> 13
- Enrollment closed: A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas (clinicaltrials.gov) - Sep 14, 2015
P2, N=48, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=20 --> 13 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Ability to Cope With Type 1 Diabetes (clinicaltrials.gov) - Sep 14, 2015
P4, N=100, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=300 --> 100
- | GSK2618960 / GSK
Trial completion: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Sep 14, 2015
P1, N=18, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=300 --> 100 Active, not recruiting --> Completed
- New P2 trial: Pre-POINT-Early Study (clinicaltrials.gov) - Sep 14, 2015
P2, N=44, Recruiting, Sponsor: Technische Universit
- Enrollment open: Mussels, Inflammation and Rheumatoid Arthritis (MIRA) (clinicaltrials.gov) - Sep 12, 2015
P=N/A, N=40, Recruiting, Sponsor: Göteborg University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- BIIB061 / Biogen
Trial completion: Single-Dose Study of a New Formulation of BIIB061 (clinicaltrials.gov) - Sep 11, 2015
P1, N=8, Completed, Sponsor: Biogen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- thyroxine / Generic mfg.
Trial withdrawal: Levothyroxine in Pregnant SLE Patients (clinicaltrials.gov) - Sep 11, 2015
P4, N=0, Withdrawn, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Terminated --> Withdrawn
- Trial completion, Enrollment change, Trial primary completion date: NARAC: Genetic Registry for Rheumatoid Arthritis (clinicaltrials.gov) - Sep 11, 2015
P=N/A, N=1062, Completed, Sponsor: North Shore Long Island Jewish Health System
Terminated --> Withdrawn Active, not recruiting --> Completed | N=3000 --> 1062 | Trial primary completion date: Dec 2015 --> Aug 2015
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - Sep 10, 2015
P3, N=717, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=3000 --> 1062 | Trial primary completion date: Dec 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? (clinicaltrials.gov) - Sep 10, 2015
P3, N=60, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting Recruiting --> Completed
- New trial: Carbohydrate Estimation Supported by the GoCARB System (clinicaltrials.gov) - Sep 10, 2015
P=N/A, N=20, Recruiting, Sponsor: University Hospital Inselspital, Berne
- New P3 trial: BOLUS: Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump (clinicaltrials.gov) - Sep 10, 2015
P3, N=22, Not yet recruiting, Sponsor: University Hospital, Brest